Edwards Lifesciences Co. (NYSE:EW - Get Free Report) VP Daniel J. Lippis sold 300 shares of the firm's stock in a transaction dated Tuesday, April 8th. The shares were sold at an average price of $70.61, for a total value of $21,183.00. Following the sale, the vice president now owns 22,863 shares in the company, valued at $1,614,356.43. The trade was a 1.30 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Edwards Lifesciences Price Performance
EW opened at $67.04 on Wednesday. The stock's 50 day moving average price is $71.54 and its 200-day moving average price is $70.65. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $95.25. The stock has a market capitalization of $39.41 billion, a PE ratio of 9.62, a price-to-earnings-growth ratio of 4.82 and a beta of 1.15. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.
Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. On average, equities research analysts predict that Edwards Lifesciences Co. will post 2.45 EPS for the current year.
Analyst Upgrades and Downgrades
EW has been the topic of several recent research reports. Canaccord Genuity Group increased their price objective on Edwards Lifesciences from $68.00 to $71.00 and gave the company a "hold" rating in a research report on Thursday, February 13th. Morgan Stanley increased their price target on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the company an "equal weight" rating in a research report on Wednesday, February 12th. Wolfe Research lowered shares of Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a report on Wednesday, February 12th. Piper Sandler increased their target price on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the company a "neutral" rating in a report on Wednesday, February 12th. Finally, Royal Bank of Canada reissued an "outperform" rating and issued a $85.00 price target on shares of Edwards Lifesciences in a research note on Wednesday, February 12th. One analyst has rated the stock with a sell rating, fourteen have given a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $79.95.
Check Out Our Latest Stock Analysis on EW
Hedge Funds Weigh In On Edwards Lifesciences
A number of institutional investors have recently bought and sold shares of EW. Centiva Capital LP bought a new position in shares of Edwards Lifesciences in the 3rd quarter worth approximately $295,000. Quantinno Capital Management LP raised its holdings in Edwards Lifesciences by 29.2% in the third quarter. Quantinno Capital Management LP now owns 53,183 shares of the medical research company's stock worth $3,510,000 after purchasing an additional 12,028 shares in the last quarter. Stifel Financial Corp lifted its position in Edwards Lifesciences by 11.9% during the third quarter. Stifel Financial Corp now owns 232,738 shares of the medical research company's stock valued at $15,358,000 after buying an additional 24,731 shares during the period. Kovitz Investment Group Partners LLC lifted its position in Edwards Lifesciences by 65.2% during the third quarter. Kovitz Investment Group Partners LLC now owns 23,039 shares of the medical research company's stock valued at $1,520,000 after buying an additional 9,093 shares during the period. Finally, National Bank of Canada FI boosted its holdings in shares of Edwards Lifesciences by 27.7% during the 3rd quarter. National Bank of Canada FI now owns 303,853 shares of the medical research company's stock valued at $20,051,000 after buying an additional 65,982 shares in the last quarter. 79.46% of the stock is owned by institutional investors.
Edwards Lifesciences Company Profile
(
Get Free Report)
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
